Metabolic studies on dysmyelinating mutant "pt" rabbit brain in vitro.
"Paralytic tremor" (pt) rabbit mutant is characterized by a severe hypomyelination of the CNS, however, it is not defined if the defect in myelinogenesis is an "assembly" or "synthesis" type. In this study, we have compared the general metabolic and biosynthetic properties of the myelinating mutant brain with unaffected controls of the same age. In the brain slices of 4 wk old "pt" rabbits the incorporation of U-[14C]glucose, 6-[3H] galactose, and U-[14C] leucine into macromolecules (total lipids and proteins, galactolipids, and myelin basic protein) was substantially elevated. In isolated myelin fraction, the total reduction of the radioactivity was followed by the increased specific activity of all examined macromolecules. The myelin to homogenate specific activity ratio was similar in control and "pt" rabbits. Distribution of the label and myelin marker, cyclic nucleotide 3'-phosphodiesterase (CNP-ase) among the membranous fractions suggests the partial inhibition of myelin formation in "pt" rabbits on the step of premyelin, unilamellar membranes. 14CO2 yields derived from differently labeled glucose were used for the evaluation of the basal oxidative metabolism in "pt" brain slices. 14CO2 production from U-[14C] glucose was normal. The depolarization of the slices by 50 mM K+ stimulated glucose oxidation to a higher extent in "pt" than in control. Hexose monophosphate pathway (HMP), the route providing much of NADPH required for lipid biosynthesis, did not change significantly by mutation. The activity of glucose 6-phosphate dehydrogenase (Glc-6-P DH), an oligodendroglia enriched, HMP connected enzyme, was slightly lower in "pt" homogenates by 13-17%, whereas CNP-ase was lowered more than 30% in the same samples. All this data suggest that the capacity for the synthesis of myelin constituents is well preserved in the mutant brain and the impairment of myelogenesis is probably caused by increased elimination of already synthesized, myelin-related components.
Domańska-Janik
K
K
Department of Neurochemistry, Polish Academy of Sciences, Warsaw, Poland.
Gajkowska
B
B
Strosznajder
J
J
Zalewska
T
T
D063309:2',3'-Cyclic Nucleotide 3'-Phosphodiesterase; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D003711:Demyelinating Diseases / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D038983:Galactolipids; D006017:Glycolipids / Q000096:biosynthesis; D008854:Microscopy, Electron; D009154:Mutation; D009185:Myelin Proteins / Q000096:biosynthesis; D009186:Myelin Sheath / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D010727:Phosphoric Diester Hydrolases; D011817:Rabbits; D014202:Tremor / Q000209:etiology / Q000378:metabolism / Q000473:pathology
D038983:Galactolipids; D006017:Glycolipids; D009185:Myelin Proteins; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D010727:Phosphoric Diester Hydrolases; D063309:2',3'-Cyclic Nucleotide 3'-Phosphodiesterase